Targeting the Brain: Rationalizing the novel methods of drug delivery to the central nervous system

Neurocritical Care

Volumn 6, Issue 3, 2007, Pages 200-212

  Joshi, Shailendra ^a   Ornstein, Eugene ^a   Bruce, Jeffrey N ^a  

^a Columbia University ^*  (United States)

Author keywords

Cerebral; Pharmacokinetics; Regional; Selective

Indexed keywords

ANTIINFECTIVE AGENT; BRADYKININ DERIVATIVE; CARVEDILOL; CLOTRIMAZOLE; CYCLOSPORIN A; CYTOKINE; DACTINOMYCIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; GLYCOPROTEIN P; IMMUNOTOXIN; LEUKOTRIENE; LEVODOPA; LOBRADIMIL; MONOCLONAL ANTIBODY; NIMODIPINE; PHENOBARBITAL; RESERPINE; RIFAMPICIN; VERAPAMIL; VINBLASTINE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD FLOW; CEREBROSPINAL FLUID; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOTHELIUM CELL; EPILEPSY; HISTOPATHOLOGY; HUMAN; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENILE DEMENTIA; STROKE; BRAIN; METHODOLOGY; RISK FACTOR; TIME;

BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; RISK FACTORS; TIME FACTORS;

EID: 34948841572     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-007-0034-8     Document Type: Review

References (87)

1. Del Zoppo GJ. Why do all drugs work in animals but none in stroke patients? 1. Drugs promoting cerebral blood flow [Review]. J Intern Med 1995;237(1):79-88.
2. Pardridge WM. Drug delivery to the brain (Review Article). J Cereb Blood Flow Metab 1997;17(7):713-31.
3. Allman JM. The evolution of big brains. Evolving brains in scientific American Library Series 1999 (First Edition), p. 158-208.
4. Omojola MF, Fox AJ, Auer RN, Vinuela FV. Hemorrhagic encephalitis produced by selective non-occlusive intracarotid BCNU injection in dogs J Neurosurg 1982;57(6):791-6.
5. Dedrick RL. Arterial drug infusion: pharmacokinetic problems and pitfalls. J Natl Cancer Inst 1988;80(2):84-9.
6. Joshi S, Hartl R, Wang M, et al. The acute cerebrovascular effects of intracarotid adenosine in nonhuman primates. Anesth Analg 2003;97(1):231-7.
7. Joshi S, Young WL, Pile-Spellman J, et al. The feasibility of intracarotid adenosine for the manipulation of human cerebrovascular resistance. Anesth Analg 1998;87:1291-8.
8. Schlosshauer B. The blood-brain barrier: morphology, molecules, and neurothelin. Bioessays 1993;15(5):341-6.
9. Vaz R, Sarmento A, Borges N, Cruz C, Azevedo I. Ultrastructural study of brain microvessels in patients with traumatic cerebral contusions. Acta Neurochir 1997;139(3):215-20.
10. Stewart PA, Hayakawa K, Farrell CL. Quantitation of blood-brain barrier ultrastructure. Microsc Res Techniq 1994;27(6):516-27.
11. Jolliet-Riant P, Tillement JP. Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol 1999;13(1):16-26.
12. Raub TJ, Kuentzel SL, Sawada GA. Permeability of bovine brain microvessel endothelial cells in vitro: barrier tightening by a factor released from astroglioma cells. Exp Cell Res 1992;199(2):330-40.
13. Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol 1996;91(1):6-14.
14. Unger RE, Oltrogge JB, von Briesen H, et al. Isolation and molecular characterization of brain microvascular endothelial cells from human brain tumors. In Vitro Cell Dev Biol Anim 2002;38(5):273-81.
15. Heistad DD, Kontos HA. Cerebral circulation (Chapter 5). In: Shepherd JT, Abboud FM, editors. Handbook of physiology: section 2: the cardiovascular system. Bethesda, MD: American Physiological Society; 1983. p. 137-82.
16. Pardridge WM, Yoshikawa T, Kang Y-S, Miller LP. Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. J Pharmacol Exp Therap 1994;268(1):14-8.
17. Neuwelt EA, Glasberg M, Frenkel E, Barnett P. Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann Neurol 1983;14(3):316-24.
18. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000;20(2):217-30.
19. Nagashima T, Ikeda K, Wu S, Kondo T, Yamaguchi M, Tamaki N. The mechanism of reversible osmotic opening of the blood-brain barrier: role of intracellular calcium ion in capillary endothelial cells. Acta Neurochir - Supplementum 1997;70:231-3.
20. Siegal T, Rubinstein R, Bokstein F, et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg 2000;92(4):599-605.
21. Zunkeler B, Carson RE, Olson J, et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 1996;85(6):1056-65.
22. Miyagami M, Tazoe M, Kagawa Y, Tsubokawa T. [The effect on the tumor vessel permeability by hyperosmotic blood brain barrier disruption]. No To Shinkei 1988;40(9):875-82.
23. Ikeda M, Bhattacharjee AK, Kondoh T, Nagashima T, Tamaki N. Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening. Biochem Biophys Res Commun 2002;291(3):669-74.
24. Kaya M, Gulturk S, Elmas I, et al. The effects of magnesium sulfate on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Life Sci 2004;76(2):201-12.
25. Kozler P, Pokorny J. Effects of intracarotid injection of methyl-prednisolone on cellular oedema after osmotic opening of the blood-brain barrier in rats. Prague Med Rep 2004;105(3):279-90.
26. Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA 1982;79(14):4420-3.
27. Chi OZ, Liu X, Weiss HR. Effects of mild hypothermia on blood-brain barrier disruption during isoflurane or pentobarbital anesthesia. Anesthesiology 2001;95(4):933-8.
28. Salahuddin TS, Johansson BB, Kalimo H, Olsson Y. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol (Berl) 1988;77(1):5-13.
29. Salahuddin TS, Kalimo H, Johansson BB, Olsson Y. Observations on exsudation of fibronectin, fibrinogen and albumin in the brain after carotid infusion of hyperosmolar solutions. An immunohistochemical study in the rat indicating longlasting changes in the brain microenvironment and multifocal nerve cell injuries. Acta Neuropathol (Berl) 1988;76(1):1-10.
30. Erdlenbruch B, Alipour M, Fricker G, et al. Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol 2003;140(7):1201-10.
31. Koenig H, Goldstone AD, Lu CY. Polyamines mediate the reversible opening of the blood-brain barrier by the intracarotid infusion of hyperosmolal mannitol. Brain Res 1989;483(1):110-6.
32. Black KL, Cloughesy T, Huang SC, et al. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 1997;86(4):603-9.
33. Warnke PC, Phillips A, Bernstein LP, Groothuis DR. The somatosensory evoked potential as a noninvasive method to determine flow rates for hyperosmotic disruption of the blood-brain barrier. Neurosurgery 1989;25(3):405-11.
34. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means [Comments by Paul L. Kornblith, Michael Pollay, Pierre-Yves Dietrich and Nicolas de Tribolet, Berislav Zlokovic]. Neurosurgery 1998;42(5):1083-100.
35. Chio CC, Baba T, Black KL. Selective blood-tumor barrier disruption by leukotrienes. J Neurosurg 1992;77(3):407-10.
36. Zhao Y, Xue Y, Liu Y, et al. Study of correlation between expression of bradykinin B2 receptor and pathological grade in human gliomas. Br J Neurosurg 2005;19(4):322-6.
37. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun 2006;340(4):1085-90.
38. Kozler P, Pokorny J. Altered blood-brain barrier permeability and its effect on the distribution of Evans blue and sodium fluorescein in the rat brain applied by intracarotid injection. Physiol Res 2003;52(5):607-14.
39. Chi OZ, Chun TW, Liu X, Weiss HR. The effects of pentobarbital on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Anesth Anal 1998;86(6):1230-5.
40. Boiardi A, Eoli M, Salmaggi A, et al. Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J Neurooncol 2001;54(1):39-47.
41. Neeves KB, Lo CT, Foley CP, Saltzman WM, Olbricht WL. Fabrication and characterization of microfluidic probes for convection enhanced drug delivery. J Control Release 2006;111(3):252-62.
42. Hall WA, Rustamzadeh E, Asher AL. Convection-enhanced delivery in clinical trials. Neurosurg Focus 2003;14(2):e2.
43. Dehouck MP, Jolliet-Riant P, Bree F, Fruchart JC, Cecchelli R, Tillement JP. Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem 1992;58(5):1790-7.
44. Bendszus M, Koltzenburg M, Bartsch AJ, et al. Heparin and air filters reduce embolic events caused by intra-arterial cerebral angiography: a prospective, randomized trial. Circulation 2004;110(15):2210-5.
45. Bendszus M, Stoll G. Silent cerebral ischaemia: hidden fingerprints of invasive medical procedures. Lancet Neurol 2006;5(4):364-72.
46. Markus H, Loh A, Israel D, Buckenham T, Clifton A, Brown MM. Microscopic air embolism during cerebral angiography and strategies for its avoidance [see comments]. Lancet 1993;341(8848):784-7.
47. Dedrick RL. Arterial drug infusion: pharmacokinetic problems and pitfalls. J Natl Cancer Inst 1988;80(2):84-9.
48. Joshi S, Wang M, Etu J, Nishanian EV. Comparison of intracarotid anesthetics for EEG silence. J Neurosurg Anesthesiol 2006;18(2):112-8.
49. Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemoth Pharmacol 1992;30(4):251-60.
50. Joshi S, Ornstein E, Young WL. Cerebral and spinal cord blood flow. In: Cottrell JE, Smith DS (Eds) Anesthesia and Neurosurgery. 4th ed. St. Louis: Mosby Inc.; 2001 pp. 19-68.
51. Lutz RJ, Dedrick RL, Boretos JW, Oldfield EH, Blacklock JB, Doppman JL. Mixing studies during intracarotid artery infusions in an in vitro model. J Neurosurg 1986;64(2):277-83.
52. Saris SC, Blasberg RG, Carson RE, et al. Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration. J Neurosurg 1991;74(5):763-72.
53. Saris SC, Shook DR, Blasberg RG, et al. Carotid artery mixing with diastole-phased pulsed drug infusion. J Neurosurg 1987;67(5):721-5.
54. Joshi S, Meyers P, Pile-Spellman J, Wang M, Sahlein D. Intracarotid verapamil decreases both proximal and distal human cerebrovascular resistance. Anesthesiology 2004;100(4):774-81.
55. Gobin YP, Cloughesy TF, Chow KL, et al. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology 2001;218(3):724-32.
56. Jones DR, Hall SD, Jackson EK, Branch RA, Wilkinson GR. Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J Pharmacol Exp Ther 1988;245(3):816-22.
57. Rapoport SI, Fitzhugh R, Pettigrew KD, Sundaram U, Ohno K. Drug entry into and distribution within brain and cerebrospinal fluid: [14C]urea pharmacokinetics. Am J Physiol 1982;242(3):R339-48.
58. Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol 1998;165(3):201-11.
59. Oldendorf WH. Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med 1974;147(3):813-5.
60. Jolliet P, Simon N, Bree F, et al. Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery. Pharm Res 1997;14(5):650-6.
61. Seelig A, Gottschlich R, Devant RM. A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc Natl Acad Sci USA 1994;91(1):68-72.
62. Greig NH, Daly EM, Sweeney DJ, Rapoport SI. Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain. Cancer Chemother Pharmacol 1990;25(5):320-5.
63. Chu CK, Bhadti VS, Doshi KJ, et al. Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido-3′-deoxythymidine. J Med Chem 1990;33(8):2188-92.
64. Pardridge WM. Blood-brain barrier transport mechanisms. In: Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B (Eds) Primer on cerebrovascular diseases. Academic Press Inc; 1997: pp. 21-5.
65. Dhanasekaran M, Polt R. New prospects for glycopeptide based analgesia: glycoside-induced penetration of the blood-brain barrier. Curr Drug Deliv 2005;2(1):59-73.
66. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996;93(24):14164-9.
67. Pardridge WM, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA 1995;92(12):5592-6.
68. Triguero D, Buciak JL, Pardridge WM. Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. J Pharmacol Exp Therap 1991;258(1):186-92.
69. Muckerheide A, Apple RJ, Pesce AJ, Michael JG. Cationization of protein antigens. I. Alteration of immunogenic properties. J Immunol 1987;138(3):833-7.
70. Fresta M, Puglisi G. Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes. Pharm Res 1999;16(12):1843-9.
71. Kanamaru K, Waga S, Kuga Y, Nakamura F, Kamata N. Transcranial Doppler pattern after intracarotid papaverine and prostaglandin E1 incorporated in lipid microsphere in patients with vasospasm. Neurol Med-Chir 1998;38 Suppl:152-5.
72. Cornford EM, Cornford ME. New systems for delivery of drugs to the brain in neurological disease. Lancet Neurol 2002;1(5):306-15.
73. Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002;10(1):73-9.
74. Moriki Y, Suzuki T, Fukami T, Hanano M, Tomono K, Watanabe J. Involvement of P-glycoprotein in blood-brain barrier transport of pentazocine in rats using brain uptake index method. Biol Pharm Bull 2004;27(6):932-5.
75. Yang ZY, Liu GQ. Effect of p-glycoprotein inhibitor combinations on drug efflux from rat brain microvessel endothelial cells. Pharmazie 2004;59(12):952-6.
76. Maines LW, Antonetti DA, Wolpert EB, Smith CD. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 2005;49(5):610-7.
77. Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005;46(6):967-9.
78. Bart J, Dijkers EC, Wegman TD, et al. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br J Pharmacol 2005;145(8):1045-51.
79. Lee YJ, Maeda J, Kusuhara H, et al. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther 2006;316(2):647-53.
80. Zhu J, Takahashi H, Nakazawa S. Human monoclonal antibody-drug conjugates in the experimental treatment of malignant gliomas-studies in vitro and in vivo. Neurol Med-Chir 1994;34(5):279-85.
81. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002;19(5):569-77.
82. Taniyama Y, Tachibana K, Hiraoka K, et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002;105(10):1233-9.
83. Taniyama Y, Tomita N, Endoh S, Kaneda Y, Ogihara T, Morishita R. [Gene transfer with ultrasound and microbubbles (optison) as a potential treatment for cardiovascular diseases]. Nippon Ronen Igakkai Zasshi - Jpn J Geriatr 2004;41(1):51-4.
84. Schleien CL, Eberle B, Shaffner DH, Koehler RC, Traystman RJ. Reduced blood-brain barrier permeability after cardiac arrest by conjugated superoxide dismutase and catalase in piglets. Stroke 1994;25(9):1830-4; discussion 4-5.
85. Schleien CL, Koehler RC, Shaffner DH, Traystman RJ. Bloodbrain barrier integrity during cardiopulmonary resuscitation in dogs. Stroke 1990;21(8):1185-91.
86. Uchino H, Elmer E, Uchino K, et al. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat. Brain Res 1998;812(1-2):216-26.
87. Ding G, Jiang Q, Li L, et al. Detection of BBB disruption and hemorrhage by Gd-DTPA enhanced MRI after embolic stroke in rat. Brain Res 2006;1114(1):195-203.